399 related articles for article (PubMed ID: 29429376)
81. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
[TBL] [Abstract][Full Text] [Related]
82. Neoadjuvant M-VAC chemotherapy and partial cystectomy for treatment of locally invasive transitional cell carcinoma of the bladder.
Simon SD; Srougi M
Prog Clin Biol Res; 1990; 353():169-74. PubMed ID: 2217415
[No Abstract] [Full Text] [Related]
83. Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer.
Moussa M; Papatsoris AG; Dellis A; Abou Chakra M; Saad W
Expert Rev Anticancer Ther; 2020 Nov; 20(11):965-983. PubMed ID: 32915676
[TBL] [Abstract][Full Text] [Related]
84. [Interdisciplinary strategies for the treatment of bladder cancer].
Bauer W; Lamche M; Schramek P
Wien Med Wochenschr; 2007; 157(7-8):153-6. PubMed ID: 17492411
[TBL] [Abstract][Full Text] [Related]
85. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience.
Kassouf W; Swanson D; Kamat AM; Leibovici D; Siefker-Radtke A; Munsell MF; Grossman HB; Dinney CP
J Urol; 2006 Jun; 175(6):2058-62. PubMed ID: 16697803
[TBL] [Abstract][Full Text] [Related]
86. Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer.
Lobo N; Martini A; Kamat AM
Expert Rev Anticancer Ther; 2022 Apr; 22(4):361-370. PubMed ID: 35212590
[TBL] [Abstract][Full Text] [Related]
87. Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages-A SEER-based Study.
Deuker M; Stolzenbach LF; Collà Ruvolo C; Nocera L; Mansour M; Tian Z; Roos FC; Becker A; Kluth LA; Tilki D; Shariat SF; Saad F; Chun FKH; Karakiewicz PI
Eur Urol Focus; 2021 Nov; 7(6):1332-1338. PubMed ID: 32962961
[TBL] [Abstract][Full Text] [Related]
88. Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, successfully treated by radical cystectomy with adjuvant chemotherapy: a case report.
Ohtaka M; Kawahara T; Kumano Y; Maeda Y; Kondo T; Mochizuki T; Ishida H; Hattori Y; Teranishi J; Miyoshi Y; Yumura Y; Yao M; Inayama Y; Uemura H
J Med Case Rep; 2016 Mar; 10():48. PubMed ID: 26951070
[TBL] [Abstract][Full Text] [Related]
89. Current perspectives in bladder cancer management.
Griffiths TR;
Int J Clin Pract; 2013 May; 67(5):435-48. PubMed ID: 23137019
[TBL] [Abstract][Full Text] [Related]
90. Organ-conserving approaches to muscle-invasive bladder cancer: future alternatives to radical cystectomy.
Zietman AL; Shipley WU; Kaufman DS
Ann Med; 2000 Feb; 32(1):34-42. PubMed ID: 10711576
[TBL] [Abstract][Full Text] [Related]
91. Immunotherapy in non-metastatic urothelial cancer: back to the 'future'.
Darling HS; Bellmunt J
Expert Opin Biol Ther; 2019 Jul; 19(7):685-695. PubMed ID: 31046476
[TBL] [Abstract][Full Text] [Related]
92. SEOM Clinical Guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2016).
Lázaro M; Gallardo E; Doménech M; Pinto Á; González-del-Alba A; Del Alba AG; Puente J; Fernández O; Font A; Lainez N; Vázquez S
Clin Transl Oncol; 2016 Dec; 18(12):1197-1205. PubMed ID: 27900539
[TBL] [Abstract][Full Text] [Related]
93. Bladder Cancer: A Review.
Lenis AT; Lec PM; Chamie K; Mshs MD
JAMA; 2020 Nov; 324(19):1980-1991. PubMed ID: 33201207
[TBL] [Abstract][Full Text] [Related]
94. Update on the guideline of guidelines: non-muscle-invasive bladder cancer.
Taylor J; Becher E; Steinberg GD
BJU Int; 2020 Feb; 125(2):197-205. PubMed ID: 31597003
[TBL] [Abstract][Full Text] [Related]
95. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
Alfred Witjes J; Lebret T; Compérat EM; Cowan NC; De Santis M; Bruins HM; Hernández V; Espinós EL; Dunn J; Rouanne M; Neuzillet Y; Veskimäe E; van der Heijden AG; Gakis G; Ribal MJ
Eur Urol; 2017 Mar; 71(3):462-475. PubMed ID: 27375033
[TBL] [Abstract][Full Text] [Related]
96. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer.
Leow JJ; Bedke J; Chamie K; Collins JW; Daneshmand S; Grivas P; Heidenreich A; Messing EM; Royce TJ; Sankin AI; Schoenberg MP; Shipley WU; Villers A; Efstathiou JA; Bellmunt J; Stenzl A
World J Urol; 2019 Jan; 37(1):61-83. PubMed ID: 30684034
[TBL] [Abstract][Full Text] [Related]
97. Invasive bladder cancer--where do we go from here?
Waters WB
J Urol; 1996 Jun; 155(6):1910-1. PubMed ID: 8618285
[No Abstract] [Full Text] [Related]
98. [Personalised medicine in urothelial bladder cancer].
Grunewald CM; Niegisch G
Aktuelle Urol; 2019 Sep; 50(5):502-508. PubMed ID: 31195416
[TBL] [Abstract][Full Text] [Related]
99. Overview of Current and Future Adjuvant Therapy for Muscle-Invasive Urothelial Carcinoma.
Nadal R; Apolo AB
Curr Treat Options Oncol; 2018 May; 19(7):36. PubMed ID: 29808294
[TBL] [Abstract][Full Text] [Related]
100. [Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments].
Todenhöfer T; Boegemann M
Urologe A; 2020 Jul; 59(7):810-816. PubMed ID: 32468092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
